The neuronal ceroid lipofuscinoses (NCLs, also known as Batten disease) are the most common childhood neurodegenerative disease. They are a group of inherited neurodegenerative disorders characterized by the accumulation of autofluorescent storage material in many cell types. Clinical features include seizures, psychomotor deterioration, and blindness, the ages and order of onset of which differ for each NCL type. An increasing number of subtypes caused by mutations in different genes are now recognized. With the advent of molecular genetics the basic genetic defect underlying each NCL phenotype is being determined, thus shedding light on the molecular basis of the NCLs and opening the way for the development of effective treatment. Four genes have been identified to date. The function of two of these is known and suggests that the primary defect in the NCLs lies in lysosomal proteolysis, the first example of this type of disease. However, since the function of the other two genes remains elusive, and at least four more genes remain to be identified, the molecular basis underlying the NCLs may be more complex than originally predicted.
INTRODUCTION
The neuronal ceroid lipofuscinoses (NCLs, also known as Batten disease) are the most common neurodegenerative disease occurring in childhood. They are a group of inherited neurodegenerative storage disorders characterized by the accumulation of an autofluorescent lipopigment (Zeman & Dyken, 1969) . This material resembles ceroid and lipofuscin and is deposited in neuronal (and other) cells, hence the name. Children are healthy at birth with normal development until onset of the disease.
Many storage diseases are now well understood. Indeed the concept of a ''storage disease'' is a disease in which a defect in a metabolic pathway leads to accumulation of a specific substrate within a cellular organelle (Neufeld, 1991) . In most storage disorders the identification of the storage material deposited led to the identification of the enzyme at fault: however, this was not possible for the NCLs. Over 30 such storage disorders resulting from defects in enzymes, associated transport systems, and other proteins that are part of the lysosomal catabolic pathway are now recognized. Up to now defects in all classes of lysosomal enzymes except for the proteases and nucleases have been discovered. The NCLs are the first reported disease in which the primary defect appears to lie in lysosomal proteolysis.
This review seeks to summarize research into the NCLs with a particular emphasis on recently reported results which are revealing the complex molecular basis of these disorders.
CLINICAL BACKGROUND
The NCLs were first described in Norway (Stengel, 1826) and around the turn of the century in the United Kingdom (Batten, 1903 (Batten, , 1914 and elsewhere (Spielmeyer, 1905; Vogt, 1905; Bielschowsky, 1913) . The incidence in Northern Europe and the United States is estimated to be in the order of 1:10,000 although it is 10-fold lower elsewhere (Santavuori, 1988; Uvebrant & Hagberg, 1997) . Three main childhood types were traditionally recognized on the basis of age of onset, clinical phenotype, and ultrastructural characterization of the storage material (Santavuori, 1988) (Table 1) . These, with their eponyms,
